The Lebanon Healthcare Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Lebanon Healthcare Journal.

September 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Press releases published on November 7, 2025

November 7, 2025

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

GlobeNewswire

November 7, 2025

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

GlobeNewswire

November 7, 2025

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

GlobeNewswire

November 7, 2025

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

GlobeNewswire

November 7, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

Cannabix Technologies announces Non-Brokered LIFE Private Placement

GlobeNewswire

November 7, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

November 7, 2025

Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

GlobeNewswire

November 7, 2025

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

GlobeNewswire

November 7, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

Exicure, Inc. Reports Third Quarter 2025 Financial Results

GlobeNewswire

November 7, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

Maximus Announces First-Ever Topical Oxytocin Cream for Mood Enhancement and Sleep Support

GlobeNewswire

November 7, 2025

All Smiles Dental Studio Launches Full Dental Implant Services and In-House Membership Plan to Support the Encinitas Community

GlobeNewswire

November 7, 2025

Protext Mobility, Inc. (OTC: TXTM) Announces Launch Phase of Its Next-Generation Investor Relations Suite and Corporate Website Modernization — Ushering in a New Era of Transparency, Innovation, and Shareholder Confidence

GlobeNewswire

November 7, 2025

PetVivo Sets Fiscal Second Quarter 2026 Conference Call for Friday, November 14, 2025 at 5:00 p.m. ET

GlobeNewswire

November 7, 2025

Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030

GlobeNewswire

November 7, 2025

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines

GlobeNewswire